Erythro-Magneto-HA-Virosome: A Bio-Inspired Drug Delivery System for Active Targeting of Drugs in the Lungs
Year: 2022
Authors: Alessio Vizzoca; Gioia Lucarini; Elisabetta Tognoni; Selene Tognarelli; Leonardo Ricotti; Lisa Gherardini; Gualtiero Pelosi; Mario Pellegrino; Arianna Menciassi; Settimio Grimaldi and Caterina Cinti
Autors Affiliation: Natl Res Council Italy, Inst Organ Synth & Photoreact ISOF, Via Gobetti 101, I-40129 Bologna, Italy; Scuola Super Sant Anna, BioRobot Inst, Piazza Martiri Liberta 33, I-56127 Pisa, Italy; Scuola Super Sant Anna, Dept Excellence Robot & AI, Piazza Martiri Liberta 33, I-56127 Pisa, Italy; Natl Res Council Italy, Natl Inst Opt INO, Via G Moruzzi 1, I-56124 Pisa, Italy; Natl Res Council Italy, Inst Clin Physiol IFC, Via G Moruzzi 1, I-56124 Pisa, Italy; Natl Res Council Italy, Inst Translat Pharmacol IFT, Via Fosso Cavaliere 100, I-00133 Rome, Italy.
Abstract: Over the past few decades, finding more efficient and selective administration routes has gained significant attention due to its crucial role in the bioavailability, absorption rate and pharmaco-kinetics of therapeutic substances. Pulmonary delivery of drug has become an attractive target of scientific and biomedical interest in the health care research area as the lung, thanks to its high permeability and large absorptive surface area and good blood supply, is capable of absorbing pharmaceuticals either for local deposition or for systemic delivery. Nevertheless, the pulmonary drug delivery is relatively complex, and strategies to mitigate the effects of mechanical, chemical and immunological barriers are required. Herein engineered erythrocytes, the Erythro-Magneto-Haemagglutinin (HA)-virosomes (EMHVs), are used as novel strategy for effi-ciently deliver drugs to the lungs. EMHV bio-based carriers exploit the physical properties of magnetic nanoparticles to achieve effective targeting after their intravenous injection, thanks to an external magnetic field. In addition, the presence of haemagglutinin fusion proteins on EMHVs? membrane allows the DDS to anchor and fuse with the target tissue and locally release the thera-peutic compound. Our results on biomechanical and biophysical properties of EMHVs, such as membrane robustness and deformability and high magnetic susceptibility, as well as their in vivo biodistribution highlight that this bio-inspired DDS is a promising platform for the controlled and lung-targeting delivery of drugs, and represents a valuable alternative to inhalation therapy to fulfill unmet clinical needs.
Journal/Review: INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume: 23 (17) Pages from: 9893 to:
More Information: This research was founded by Fase1-Sardegna Ricerche srl, PARDRUG grant, funding number: 54/0071296.KeyWords: engineered erythrocytes, cell-based drug delivery systems, pulmonary drug delivery, active targeting, magnetic platformDOI: 10.3390/ijms23179893Citations: 3data from “WEB OF SCIENCE” (of Thomson Reuters) are update at: 2024-10-27References taken from IsiWeb of Knowledge: (subscribers only)Connecting to view paper tab on IsiWeb: Click hereConnecting to view citations from IsiWeb: Click here